Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Big 4 Private Equity Firms In Brighter Mood; Falling Investment In Biotech
Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...